Genentech, the US biotech arm of Swiss pharma giant Roche, is building a new small-batch biologics manufacturing facility at its Oceanside campus in California, USA...
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...
Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process...
US scientific equipment manufacturer Thermo Fisher Scientific and China-based CDMO Innoforce have formed a joint venture to own and operate a new pharma services facility...
25.02.2019
- Catalent appointed Kay Schmidt as senior vice president, Technical Operations. In this new role, Schmidt will report to Alessandro Maselli, who earlier this month was appointed as...
10.01.2019
- US-based Catalent is investing $200 million in its biologics business to expand drug substance manufacturing capacity and fill/finish capabilities at its sites in Madison...
30.04.2018
- US drugmaker Catalent announced key organizational changes within its biologics business. Tedd Green, former president of Cook Pharmica, has been appointed as senior vice president...
30.03.2018
- With a market value of $62 billion in 2016, the contract development and manufacturing organization (CDMO) industry has a compound annual growth rate (CAGR) of 6-7 %, according to...
